BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT
Delisted
BMY.RT was delisted on the 31st of December, 2020.
581 hedge funds and large institutions have $1.89B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 91 increasing their positions, 214 reducing their positions, and 61 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
57% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 214
Holders
581
Holding in Top 10
11
Calls
$24.4M
Puts
$1.24M
Top Buyers
| 1 | +$32.2M | |
| 2 | +$21.5M | |
| 3 | +$20.7M | |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$20.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$12.5M |
Top Sellers
| 1 | -$45.1M | |
| 2 | -$16.2M | |
| 3 | -$13.5M | |
| 4 |
HM
HealthCor Management
New York
|
-$13.3M |
| 5 |
Renaissance Technologies
New York
|
-$12.1M |